Conclusion
From the perspective of the Chinese health-care system, the current model predicted that pembrolizumab monotherapy is more likely to be a cost-effective first-line strategy for patients with dMMR/MSI-H advanced or metastatic CRC. When PAP is available, pembrolizumab monotherapy is the dominant treatment strategy. The reported conclusions may be helpful to physicians, mCRC patients and health management agencies in their decision-making processes.